Compass Pathways stock rating reiterated at Buy by BTIG on approval outlook

BTIG reiterated a Buy rating and $14.00 price target on Compass Pathways, implying about 29% upside from the current $10.81 share price. The firm said COMP360 remains very likely approvable, with a new CNPV voucher potentially shortening the final approval step and treatment-center economics comparing favorably with SPRAVATO. Compass also reported Q1 EPS of -$0.30 versus -$0.43 consensus, and RBC lifted its target to $22.00 from $21.00.

Analysis

The market is starting to price CMPS less as a binary clinical-risk story and more as a commercialization-duration story: the key question is no longer only whether approval happens, but whether the label and workflow economics make the asset “must-have” for treatment centers. That matters because the first wave of buyers is likely to be providers that already invested in SPRAVATO infrastructure; if COMP360 can slot into existing rooms and staffing patterns, adoption could be faster than a typical novel-launch curve. The real moat is not just regulatory clearance, but whether reimbursement supports enough gross profit per chair-hour to incentivize centers to prioritize one more psychedelic session over alternative psychiatric utilization.

The second-order winner may be the center-network ecosystem rather than only CMPS itself. Any facility that can monetize both ketamine-like and psilocybin-like workflows gains throughput optionality, while pure-play SPRAVATO economics could face pressure if COMP360 delivers comparable clinical stickiness with better scheduling efficiency. That creates a subtle channel conflict: providers may become more willing to trial COMP360 early if it increases daily revenue per room, even if physician enthusiasm is only moderate.

The biggest near-term risk is not approval delay; it is a “good enough” approval paired with underwhelming reimbursement or noisy duration-of-response data that makes payers and prescribers cautious. The stock has already rerated on execution credibility, so the next leg higher likely requires a second catalyst within 3-6 months: cleaner Part B durability data, positive payer language, or evidence that centers can actually convert the workflow advantage into utilization. Without that, the move risks stalling into a valuation air pocket as investors wait for launch specifics rather than trading the regulatory narrative.

Key Decisions for Investors

• Stay long CMPS into the next catalyst window, but hedge with a 3-6 month put spread to protect against reimbursement disappointment; upside remains meaningful if launch economics prove real, but the stock is now sensitive to any delay in payer clarity.
• Add on pullbacks rather than chasing strength: scale into CMPS on 5-8% retracements, since the near-term setup is less about headline approval odds and more about optionality into durability and launch data over the next 1-2 quarters.
• Pair trade: long CMPS / short a basket of slower-growth psychiatry incumbents that rely on repetitive administration economics; if COMP360 proves more chair-efficient, the market may reward throughput winners over established but less scalable treatment models.
• For event-driven accounts, buy CMPS call spreads 3-6 months out to express approval-plus-launch upside while limiting valuation risk if the market fades the story after confirmation.
• Reduce exposure if the next data release implies shorter-than-expected response duration; that would weaken both physician enthusiasm and reimbursement leverage, cutting off the core adoption thesis even with approval in hand.